Details for New Drug Application (NDA): 219830
✉ Email this page to a colleague
NDA 219830 describes TOFACITINIB CITRATE, which is a drug marketed by Auson, Hikma, MSN, Saptalis Pharms, Sun Pharm Inds Inc, Ajanta Pharma Ltd, Apotex, Aurobindo Pharma Ltd, Biocon Pharma, Dexcel, Orient Pharma, Sciegen Pharms, Sinotherapeutics Inc, Zydus Pharms, Breckenridge, Concord Biotech Ltd, Macleods Pharms Ltd, Micro Labs, Somerset Theraps Llc, Specgx Llc, and Yaopharma Co Ltd, and is included in twenty-six NDAs. It is available from twenty-one suppliers. Additional details are available on the TOFACITINIB CITRATE profile page.
The generic ingredient in TOFACITINIB CITRATE is tofacitinib citrate. There are twelve drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the tofacitinib citrate profile page.
The generic ingredient in TOFACITINIB CITRATE is tofacitinib citrate. There are twelve drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the tofacitinib citrate profile page.
Summary for 219830
| Tradename: | TOFACITINIB CITRATE |
| Applicant: | Orient Pharma |
| Ingredient: | tofacitinib citrate |
| Patents: | 0 |
Pharmacology for NDA: 219830
| Mechanism of Action | Janus Kinase Inhibitors |
Suppliers and Packaging for NDA: 219830
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TOFACITINIB CITRATE | tofacitinib citrate | TABLET, EXTENDED RELEASE;ORAL | 219830 | ANDA | Exelan pharmaceuticals,Inc | 76282-816 | 76282-816-30 | 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (76282-816-30) |
| TOFACITINIB CITRATE | tofacitinib citrate | TABLET, EXTENDED RELEASE;ORAL | 219830 | ANDA | Orient Pharma Co., Ltd. Yunlin Plant | 76333-111 | 76333-111-15 | 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (76333-111-15) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | EQ 11MG BASE | ||||
| Approval Date: | Jun 9, 2026 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
